On Monday, March 31, a court in the Eastern District of Texas found unlawful and vacated the Food and Drug Administration’s ...

Yesterday the U.S. District Court for the Northern District of California granted summary judgment to FDA and drug ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

The summary presents key developments affecting the health sector, including disruptions in the FDA due to Trump's layoffs, ...

Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, Zepbound and Mounjaro, by suing two compounding pharmacies — Strive Pharmacy and ...

The health sector faces significant challenges due to recent actions from the Trump administration. Key issues include tariffs on Indian pharmaceuticals, FDA staffing changes, legal battles over drug ...

Legal Challenges to the FDA’s Decision to End Semaglutide and Tirzepatide Shortage The plaintiffs argue that the FDA’s decision to remove semaglutide from the federal drug shortage list is “ ...

A lower court will reconsider whether the agency should have considered an e-cigarette manufacturer's marketing plan.